Xconomy: With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

has become the drug maker to bet that synthetic messenger RNA molecules () can be a new source for .

serverpoint hosting banner

This morning, the New York pharma company cut a deal with , of Germany, to co-develop mRNA vaccines for flu prevention.

BioNTech will run the initial human tests on these treatments, then hand the programs off to Pfizer (NYSE: PFE) for further development.

Through an unspecified upfront cash payout, equity, and research payments, BioNTech could net a total of $120 million in the near-term for signing the deal. It could ultimately see another $305 million in downstream… Read more »

UNDERWRITERS AND PARTNERS

Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.